Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRITON2: Phase 2 Study of Rucaparib in Metastatic Castration-Resistant Prostate Cancer with Homologous Recombination Deficiency
2016-003162-13Phase 2Unknown
- Sponsor
- Clovis Oncology
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rucaparib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Clovis Oncology. Primary endpoints: Objective response rate in HRD-positive mCRPC and Duration of response. Status: unknown.
02
Drugs
rucaparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2016-003162-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003162-13.